Commercial Insight: Multiple Sclerosis - Next Generation Therapies Signal the Start of a New Era Now at ReportsandReports
Datamonitor expects Novartis's Gilenia (fingolimod) to launch at the end of 2010 as a first-line therapy, while Merck Serono's oral cladribine is anticipated to launch at the start of 2011.
View full press release